GemPharmatech

Overview

GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and preclinical research services to global pharmaceutical, biotech, and research organizations. Founded in 2017, the company specializes in developing animal models using cutting-edge gene-editing technologies including CRISPR/Cas9 and ES cell targeting.

Core Capabilities

Model Development & Resources:

• Library of 25,000+ mouse strains with ~30,000 proprietary genetically modified models
• Conditional knockout (cKO) and knockout (KO) mouse models ("Spotted Mouse Program")
• Humanized mouse models (gene humanization, cellular/tissue humanization, immune reconstitution, microbiota humanization)
• Immunodeficient mouse strains including NCG mice (T cell, B cell, NK cell deficient)
• Germ-free mouse strains
• NeoMab® fully human antibody transgenic mice for antibody drug discovery
• Wild-derived mouse models from diverse geographic origins
• Disease models covering 1,000+ validated phenotypes across oncology, metabolic, cardiovascular, autoimmune, neurological, hematological, and rare disease areas

Technical Services:

• Custom gene editing (transgenic, KO, KI, point mutation)
• Custom breeding services (biocleaning, assisted reproduction, genetic material cryopreservation, surrogate breeding)
• Quality control testing (microbial detection, SNP genotyping)
• Animal facility management and housing
• Preclinical pharmacology and efficacy evaluation (in vitro and in vivo)
• Target validation and non-GLP safety assessment

Infrastructure

• 6,000+ annual model generation capacity
• 230,000+ SPF cage capacity
• 30,000+ square meters of SPF facilities
• 1,700+ employees globally
• 10 global headquarters and subsidiary locations
• Designated as a co-builder of the National Genetic Engineering Mouse Resource Library by China's Ministry of Science and Technology

Disease Focus Areas

Oncology, metabolic and cardiovascular disease, autoimmune disease, neurodegeneration, infectious disease, and rare disease.